← All Carisma Therapeutics INC filings

Carisma Therapeutics INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

OTC.Pink
CARM
Carisma Therapeutics INC
10-K/A: Carisma Therapeutics Files Amendment to 10-K, Providing Detailed Insight into Executive Compensation and Corporate Governance
Carisma Therapeutics files an amendment to its 2024 Annual Report on Form 10-K, including detailed information on directors, executive compensation, corporate governance, and related matters omitted from the original filing.
OTC.Pink
CARM
Carisma Therapeutics INC
10-K: Carisma Therapeutics Announces Strategic Shift, Halts R&D, Explores Asset Sales
Carisma Therapeutics halts research and development, explores strategic alternatives including asset sales, and prepares for a potential wind down to preserve cash.
OTC.Pink
CARM
Carisma Therapeutics INC
10-K: Carisma Therapeutics Inc. Announces Strategic Shift, Prioritizing Novel CAR-Monocyte Therapy
Carisma Therapeutics Inc. is focusing its clinical development on CT-0525, a novel CAR-Monocyte therapy, while suspending new patient enrollment in its CT-0508 trial and pausing CT-1119 development.